IDP Pharma

IDP Pharma is developing cancer therapies that target intrinsically disordered proteins (IDPs), a novel class of disease drivers, by modulating intra-protein interactions, and leads the field with a clinical-stage asset that degrades cMyc, a key oncogene in 70% of cancers.